BR0016339A - Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto - Google Patents

Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto

Info

Publication number
BR0016339A
BR0016339A BR0016339-2A BR0016339A BR0016339A BR 0016339 A BR0016339 A BR 0016339A BR 0016339 A BR0016339 A BR 0016339A BR 0016339 A BR0016339 A BR 0016339A
Authority
BR
Brazil
Prior art keywords
lcrf
human
complex
obesity
conjugated
Prior art date
Application number
BR0016339-2A
Other languages
English (en)
Inventor
Nnochiri N Ekwuribe
Original Assignee
Nobex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp filed Critical Nobex Corp
Publication of BR0016339A publication Critical patent/BR0016339A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

"COMPOSIçãO DE LCRF, CONJUGADO DE LCRF, COMPOSIçãO DE PEPTìDEO, COMPLEXO DE LCRF CONJUGADO A LIGANDO MúLTIPLO, COMPLEXO DE POLISSORBATO, COMPLEXO DE LCRF CONJUGADO, AQUOSAMENTE SOLúVEL, ESTáVEL, FORMA DE DOSAGEM DE ADMINISTRAçãO ORAL PARA O TRATAMENTO DA OBESIDADE, MéTODOS DE TRATAMENTO DA OBESIDADE EM UM PACIENTE MAMìFERO HUMANO OU NãO HUMANO, DE TRATAMENTO DE MODO PROFILáTICO OU INTERVENCIONAL DA OBESIDADE POTENCIAL OU DESENVOLVIDA EM UM PACIENTE MAMìFERO HUMANO OU NãO HUMANO E DE PROLONGAMENTO DA ATIVIDADE DE LCRF EM UM SISTEMA IN VIVO OU IN VITRO, E, COMPOSTO". Proteínas e/ou peptídeos, tais como o fator de liberação de colecistocinina luminal (LCRF), são conjugados com oligómeros e polímeros anfifílicos. Tais conjugados podem modular o perfil farmacocinético das proteínas e/ou peptídeos, melhorando deste modo a sua utilidade clínica. Tais conjugados também podem estabilizar e liberar as proteínas e/ou peptídeos, tais como LCRF, aos receptores no intestino sem a absorção na corrente sang³ínea.
BR0016339-2A 1999-12-13 2000-12-11 Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto BR0016339A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/459,443 US6638906B1 (en) 1999-12-13 1999-12-13 Amphiphilic polymers and polypeptide conjugates comprising same
PCT/US2000/033592 WO2001041812A2 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same

Publications (1)

Publication Number Publication Date
BR0016339A true BR0016339A (pt) 2002-08-27

Family

ID=23824795

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016339-2A BR0016339A (pt) 1999-12-13 2000-12-11 Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto

Country Status (18)

Country Link
US (2) US6638906B1 (pt)
EP (1) EP1237580A2 (pt)
JP (1) JP2003516366A (pt)
KR (1) KR20020068053A (pt)
CN (1) CN1434725A (pt)
AU (1) AU2087501A (pt)
BR (1) BR0016339A (pt)
CA (1) CA2394928A1 (pt)
CZ (1) CZ20021990A3 (pt)
HK (1) HK1049283A1 (pt)
HU (1) HUP0300133A2 (pt)
IL (1) IL150119A0 (pt)
MX (1) MXPA02005885A (pt)
NO (1) NO20022793L (pt)
PL (1) PL359174A1 (pt)
RU (1) RU2002118709A (pt)
WO (1) WO2001041812A2 (pt)
ZA (1) ZA200204603B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425138D0 (en) 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
AU2003202026A1 (en) 2002-01-16 2003-09-02 Dynal Biotech Asa Method for isolating nucleic acids and protein from a single sample
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
AU2003297583B2 (en) * 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
AU2004285558A1 (en) * 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain
SG153865A1 (en) 2004-06-25 2009-07-29 Takeda Pharmaceutical Metastin derivatives and use thereof
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
WO2007011959A2 (en) * 2005-07-15 2007-01-25 Quintessence Biosciences, Inc. Methods and compositions for extracting membrane proteins
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
EP2314609B1 (en) * 2008-07-30 2016-11-30 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
RU2013141079A (ru) * 2011-03-01 2015-04-10 Ново Нордиск А/С Антагонические лиганды dr3
CN103740661B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CN103740659B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
US20140039158A1 (en) * 2012-07-25 2014-02-06 Belrose Pharma, Inc. Polymeric conjugates and methods of preparing the same
CN106729735B (zh) * 2017-03-09 2020-05-12 国家纳米科学中心 一种pH敏感的多肽聚合物及其制备方法和应用
JP2021521231A (ja) * 2018-04-16 2021-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 熱安定性を改善するためのタンパク質製剤のための添加剤
KR20240026573A (ko) * 2022-08-22 2024-02-29 부산대학교 산학협력단 폴리소르베이트-숙신산-카르니틴 복합체 및 이를 포함하는 생리활성 물질 또는 약물 전달용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1997015671A1 (en) 1995-10-26 1997-05-01 Board Of Regents, The University Of Texas System Luminal cholecystokinin-releasing factor
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1998058927A1 (en) 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Also Published As

Publication number Publication date
MXPA02005885A (es) 2002-10-23
IL150119A0 (en) 2002-12-01
US6638906B1 (en) 2003-10-28
KR20020068053A (ko) 2002-08-24
NO20022793D0 (no) 2002-06-12
HK1049283A1 (zh) 2003-05-09
CA2394928A1 (en) 2001-06-14
EP1237580A2 (en) 2002-09-11
WO2001041812A2 (en) 2001-06-14
RU2002118709A (ru) 2004-02-27
NO20022793L (no) 2002-08-13
CZ20021990A3 (cs) 2002-11-13
HUP0300133A2 (en) 2003-05-28
WO2001041812A3 (en) 2002-03-21
CN1434725A (zh) 2003-08-06
AU2087501A (en) 2001-06-18
PL359174A1 (en) 2004-08-23
US20040092449A1 (en) 2004-05-13
ZA200204603B (en) 2003-11-26
JP2003516366A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
BR0016339A (pt) Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto
Guggi et al. Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin
Washington et al. Physiological pharmaceutics: barriers to drug absorption
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
DE69804974D1 (de) Opioid-konjugate mit endogenen trägerproteinen
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
ATE107514T1 (de) Stabilisierte protein- oder peptidkonjugate.
Temming et al. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels
GR1002847B (el) Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
Ratnaparkhi Mukesh et al. Colon targeted drug delivery system
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
Mezö et al. Synthesis, Conformation, Biodistribution, and Hormone-Related in Vitro Antitumor Activity of a Gonadotropin-Releasing Hormone Antagonist− Branched Polypeptide Conjugate
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
Banzato et al. Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate
Bridges et al. Radiolabeling, stability, and body distribution in rats, of low molecular weight polylactide homopolymer and polylactide–polyethyleneglycol copolymer
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso
SE8900752L (sv) Farmaceutisk komposition
JP2002514404A5 (pt)
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
Hyacinthe et al. Inhibition of bladder tumor cell implantation in cauterized urothelium, without inhibition of healing, by a fibronectin-related peptide (GRGDS)
Varani Buccal and Topical drug delivery
RU96113045A (ru) Составы эстрамустина с улучшенными фармацевтическими свойствами
Pantzar et al. P6 Small intestinal paracellular permeability include macro-molecules with molecular weights around 10000 Da
Mirchandani Intestinal absorption of anti-HIV drugs: Development of multi-loop in situ technique, characterization and mechanistic analysis.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01)